Skip to main content
Clinical Trials/NCT04541966
NCT04541966
Completed
Not Applicable

What Happens to First Trimester Nuchal Translucency Greater Than or Equal 99ème Percentile and Inferior 3.5 mm

University Hospital, Montpellier1 site in 1 country230 target enrollmentMay 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Nuchal Translucency
Sponsor
University Hospital, Montpellier
Enrollment
230
Locations
1
Primary Endpoint
Pregnancies without ultrasound or genetic abnormalities
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

First trimester nuchal translucency is a call point for genetic abnormalities and birth defects. Nuchal translucency varies with LCC and therefore with gestational age as described by Chung et al who created a 99th percentile curve of nuchal translucency versus LCC. The majority of centers use the 3.5 mm cutoff as the 99th percentile instead of using nuchal translucency based on LCC. The objective of this study is to compare the fate of nuchal hyperclites> = 99th p but <3.5mm versus 3.5mm. For this the investigators have studied the ultrasound and genetic abnormalities. The investigators were also interested in the pregnancy outcomes and the percentage of pregnancies in the group> = 99th p and <3.5mm that would have been sampled for a high combined risk for trisomy 21, and therefore to determine the benefit of a systematic sample. for HCN as well as the interest of performing an ACPA that would not be performed on a sample with a high risk of trisomy 21.

Registry
clinicaltrials.gov
Start Date
May 1, 2020
End Date
September 1, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Pregnancies without ultrasound or genetic abnormalities

Time Frame: immediate antenatal and postnatal period

Pregnancies without ultrasound or genetic abnormalities

Secondary Outcomes

  • ACPA interest(immediate antenatal and postnatal period)
  • percentage of samples for high risk combined for trisomy 21(immediate antenatal and postnatal period)
  • Pregnancy outcomes(immediate antenatal and postnatal period)

Study Sites (1)

Loading locations...

Similar Trials